Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases

Partnership combines Chemify's AI-powered molecular design and synthesis with Sanacor's expertise in mitochondrial dysfunction and cardiometabolic disease

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Chemify, a deep-tech pioneer in AI-driven molecular discovery and automated synthesis, has announced a collaboration with Sanacor, a biotechnology company developing therapies targeting mitochondrial dysfunction in cardiometabolic diseases. The partnership aims to accelerate the discovery of novel, orally available small-molecule inhibitors for the treatment of cardiometabolic diseases, with an initial focus on diabetic cardiovascular disease.

Why it matters

Diabetic cardiovascular disease is a leading cause of morbidity and mortality for those with diabetes, yet there are currently no approved therapies that directly address the underlying vascular dysfunction. By combining Chemify's advanced computational and automation capabilities with Sanacor's deep expertise in mitochondrial biology and cardiometabolic disease, the collaboration has the potential to yield first-in-class therapeutic candidates to address this major unmet medical need.

The details

The collaboration will leverage Chemify's Chemputation technology, which integrates machine learning-based molecular design, automated synthesis, and a universal programming language for chemistry. This will be combined with Sanacor's research demonstrating the central role of dysregulated mitochondrial dynamics in driving diabetic cardiovascular disease and endothelial dysfunction. Preclinical studies by Sanacor have shown that pharmacological modulation of this pathway can restore vascular function in type 2 diabetes models.

  • The collaboration was announced on February 25, 2026.

The players

Chemify

A deep-tech pioneer of Chemputation, a technology that combines machine learning-based molecular discovery and automated, robotic synthesis.

Sanacor Inc.

A biotechnology company developing therapies that target mitochondrial dysfunction in cardiometabolic diseases.

Lee Cronin

CEO and Founder of Chemify.

Michael Widlansky, MD, MPH, FACC, FAHA

CEO and Co-founder of Sanacor, with expertise in cardiometabolic disease and the role of mitochondrial dysfunction.

Got photos? Submit your photos here. ›

What they’re saying

“Our platform allows us to rapidly design, make and refine novel, highly efficacious small molecules in a tightly integrated workflow, giving teams the ability to move from biological insight to optimized compounds with speed and confidence”

— Lee Cronin, CEO and Founder, Chemify (BusinessWire)

“Our research has consistently shown that mitochondrial dysfunction is a root cause of vascular disease in diabetes. Targeting the dysregulation represents a fundamentally different approach where we can address disease biology”

— Michael Widlansky, MD, MPH, FACC, FAHA, CEO and Co-founder, Sanacor (BusinessWire)

What’s next

The collaboration between Chemify and Sanacor aims to rapidly advance the discovery and development of novel small-molecule therapies targeting mitochondrial dysfunction in cardiometabolic diseases, with an initial focus on diabetic cardiovascular disease.

The takeaway

By combining Chemify's AI-powered molecular design and synthesis capabilities with Sanacor's deep expertise in mitochondrial biology and cardiometabolic disease, this collaboration has the potential to yield breakthrough therapies that address the underlying causes of diabetic cardiovascular disease, a major unmet medical need affecting millions of patients worldwide.